RE:Another Ph1b launch in 2020?Yajne wrote: Wording in last paragraph suggests that we should see another indication launched in a few months. Doesn't say ALL 20 sites have to be open, rather 'the majority'. Could next indication be funded via JV? Seems to me that increased Ph2 activity should stir the interest of Pharma, especially when patient data starts rolling in..
When Study II is well underway with the majority of the approximately 20 study sites open and recruiting patients, the Company expects to expand the breadth of oncological indications as Theralase has now developed significant expertise and intellectual property of its patented PDCs, in the area of photopharmacology and anti-cancer therapy, with data acquired from preclinical models of human disease. Extensive preclinical research has been conducted with Rutherrin®, a patented formulation of the Company's lead PDC (TLD-1433) combined with transferrin. The Company has demonstrated significant anti-cancer efficacy of Rutherrin®, across numerous preclinical models; including: GlioBlastoma Multiforme ("GBM") and Non-Small Cell Lung Cancer ("NSCLC").
So what do you think will come first: the 1B for GBM or lung cancer?